Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 228

Similar articles for PubMed (Select 8874076)

1.

Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection.

Thompson KA, Strayer DR, Salvato PD, Thompson CE, Klimas N, Molavi A, Hamill AK, Zheng Z, Ventura D, Carter WA.

Eur J Clin Microbiol Infect Dis. 1996 Jul;15(7):580-7.

PMID:
8874076
2.

[Effect of Vimang in HIV/AIDS patients].

Gil del Valle L, Serrano López T, Calderón Fuentes O, Núñez Sánchez F, Tápanes Peraza RD, Pérez Avila J.

Rev Cubana Med Trop. 2010 Sep-Dec;62(3):200-6. Spanish.

PMID:
23437549
3.

A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL; Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM.

PLoS One. 2012;7(3):e31334. doi: 10.1371/journal.pone.0031334. Epub 2012 Mar 14.

4.

Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.

Sangkitporn S, Shide L, Klinbuayaem V, Leenasirimakul P, Wirayutwatthana NA, Leechanachai P, Dettrairat S, Kunachiwa W, Thamlikitkul V.

Southeast Asian J Trop Med Public Health. 2005 May;36(3):704-8.

PMID:
16124442
5.

Mismatched double-stranded RNA: polyI:polyC12U.

[No authors listed]

Drugs R D. 2004;5(5):297-304.

PMID:
15357629
6.

[HIV-infection and its implications on allergic diseases].

Montero Mora P, Suárez Núñez F, Tinajero Castañeda OA, González Pérez Mdel C, Guidos Fogelbach GA.

Rev Alerg Mex. 2004 Mar-Apr;51(2):54-60. Spanish.

PMID:
15237910
7.

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B; AIDS Clinical Trials Group 248 Study Team.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87.

PMID:
15097300
8.

Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.

Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW.

AIDS. 2003 Nov 7;17(16):2345-9.

PMID:
14571186
9.

Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.

Hirsch MS, Steigbigel RT, Staszewski S, McMahon D, Fischl MA, Hirschel B, Squires K, DiNubile MJ, Harvey CM, Chen J, Leavitt RY; Protocol 039 Study Group.

Clin Infect Dis. 2003 Oct 15;37(8):1119-24. Epub 2003 Sep 18.

10.

A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.

Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.

West Afr J Med. 2002 Apr-Jun;21(2):83-6.

PMID:
12403023
11.

A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.

Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, Fox L, Roe J, Kundu S, Pollard R; AACTG 325 Protocol Team.

AIDS. 2002 May 24;16(8):1147-54.

PMID:
12004273
12.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
13.

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

Saag MS, Tebas P, Sension M, Conant M, Myers R, Chapman SK, Anderson R, Clendeninn N; Virqacept Collaborative Study Group.

AIDS. 2001 Oct 19;15(15):1971-8.

PMID:
11600825
14.

Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?

Arduino JM, Fischl MA, Stanley K, Collier AC, Spiegelman D.

AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1099-105.

PMID:
11522179
17.

New "ThetaSwitch" drug may increase long-term survival in HIV disease.

[No authors listed]

J Int Assoc Physicians AIDS Care. 1996 Apr;2(4):59.

PMID:
11363523
19.

Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.

Ruiz L, Romeu J, Ibáñez A, Cabrera C, Puig T, Morales MA, Sirera G, Clotet B.

Antivir Ther. 1996 Dec;1(4):220-4.

PMID:
11324824
20.

Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.

Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J.

Antivir Ther. 1997 Jul;2(3):175-83.

PMID:
11322272
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk